Jenny Liu, MD
Internal Medicine · East Brunswick, NJNPI 1720016108
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,420 of the $3,874 with a category attached, or 88.3%. It is spread thinly across 25 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,205 and has fallen 52.7% since, to $571 in 2025.
Across 179 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$605
- Eli Lilly$534
- Novo Nordisk$507
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$502
- Intra-sana Laboratories$274
- Bayer$241
- plus $1K from 19 others
Across 314 payments — averaging $1936.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$289K
- Novo Nordisk AS$241K
- GSK$53K
- Bausch Health US, LLC$15K
- Eisai Inc.$10K
What the payments were for
- Travel & lodging$45312%
- Food & beverage$3,42088%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 27 | $605 |
| Eli Lilly | 3 | $534 |
| Novo Nordisk | 21 | $507 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 41 | $502 |
| Intra-sana Laboratories | 12 | $274 |
| Bayer | 6 | $241 |
| Corcept Therapeutics | 8 | $218 |
| AbbVie(2 entities) | 14 | $203 |
| Gilead | 5 | $154 |
| Lilly USA, LLC | 7 | $97 |
| Alkermes, Inc. | 6 | $95 |
| Exact Sciences | 3 | $79 |
| Amarin Pharma, Inc. | 5 | $74 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| Pfizer | 2 | $40 |
| GSK | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Amgen | 2 | $30 |
| Dexcom, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $20 |
| Boston Scientific | 1 | $16 |
| Ardelyx, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$237
- Kerendia$125
- Reltone 200 Mg$111
- GLYCATE$111
- Reltone 400 Mg$111
- Korlym$108
- ULTOMIRIS$101
How this compares
$3,874 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 71 | $87,153 |
| JardianceEmpagliflozin | 50 | $50,329 |
| TrulicityDulaglutide | 40 | $46,924 |
| OzempicSemaglutide | 36 | $45,080 |
| JanumetSitagliptin Phos/Metformin Hcl | 30 | $27,358 |
| MounjaroTirzepatide | 22 | $25,254 |
| LinzessLinaclotide | 24 | $23,625 |
| VascepaIcosapent Ethyl | 50 | $21,913 |
| EliquisApixaban | 25 | $19,652 |
| VemlidyTenofovir Alafenamide | 14 | $18,562 |
| JanuviaSitagliptin Phosphate | 13 | $15,458 |
| XareltoRivaroxaban | 12 | $8,116 |
| Icosapent Ethyl | 36 | $6,939 |
| Atorvastatin Calcium | 212 | $2,780 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 150 | $1,913 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $605 | $87,15371 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $97 | $72,17762 claims |
| Novo NordiskOzempic | $507 | $45,08036 claims |
| AbbVieLinzess | $203 | $23,62524 claims |
| PfizerEliquis | $40 | $19,65225 claims |
| GileadVemlidy | $154 | $18,56214 claims |
| Johnson & JohnsonXarelto | $13 | $8,11612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in East Brunswick
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.